Shareholders of BRAIN Biotech AG approved all agenda items with a broad majority at the company's 2026 Annual General Meeting for the 2024/25 financial year. Dr. Ursula La Cognata, managing partner of ybe (Your Biotech Experts Partnership), was elected to the Supervisory Board for a four-year term, having previously been appointed by the Darmstadt Local Court effective July 11, 2025. The detailed voting results and all other documents relating to the 2026 Annual General Meeting are available on the BRAIN Biotech AG website: https://www.brain-biotech-group.com/en/investors/annual-general-meeting/annual-general-meeting-2026/.
Supervisory Board Chairman Dr. Michael Majerus expressed confidence in the company's future, stating that BRAIN Biotech AG has many positive development opportunities due to its successful product business, strong market position in contract research, expected revenues from monetization initiatives and pharmaceutical project licensing, and further product innovations from the BRAINBioIncubator. This outlook is significant for investors and the biotechnology sector as it highlights the company's diversified revenue streams and innovation pipeline in a competitive industry.
CEO Adriaan Moelker emphasized the company's two-pillar strategy, which combines the product-oriented BRAINBiocatalysts segment with the research-intensive BRAINBioIncubator segment. This approach allows the company to monetize investments, achieve scientifically based breakthroughs, and organically expand a profitable, scalable, enzyme-focused business. Moelker noted that the company's relatively small size enables quick and flexible responses to customer needs with short communication channels, offering innovative biotechnological solutions. Maintaining this agility is crucial as the company aims for stronger growth, potentially impacting its competitive edge in the biotechnology market.
Moelker also reported on the consolidation of production and sales for enzymes and food ingredients for the baking and beverage industries at a new location in the Netherlands. The new building, which includes a modern baking application center, laboratory, and production areas, is nearing completion. This consolidation could enhance operational efficiency and support the company's expansion in the food industry, relevant for stakeholders in sustainable food production. For more information about the company's broader operations, visit: https://www.brain-biotech-group.com.
The BRAIN Biotech Group is a leader in researching, developing, and producing specialty enzymes, focusing on the food and life sciences industries. It develops microbial production strains and scalable bioprocesses for economic production and offers customized biological solutions for more sustainable products and efficient processes. In the 2024/25 fiscal year, the group generated revenue of €49.6 million with around 280 employees, indicating its role in advancing biotechnology applications globally. The company's activities are divided into BRAINBiocatalysts and BRAINBioIncubator, with operations in the UK, continental Europe, and the US, positioning it as a key player in international biotech markets.
